The World Health Organization (WHO) on Thursday listed the Pfizer/BioNTech vaccine as the first such drug to receive its emergency validation since the coronavirus disease 2019 (Covid-19) outbreak began a year ago.
“This is a very positive step towards ensuring global access to Covid-19 vaccines,” said Dr. Mariangela Simao, WHO assistant director-general for access to medicines and health products.
“But I want to emphasize the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere,” she said.
The WHO’s Emergency Use Listing opens the door for countries to speed up their regulatory approval processes to import and administer the vaccine.
It also enables the UN children’s agency UNICEF and the Pan American Health Organization to procure the vaccine for distribution to countries in need.
“The WHO and our partners are working night and day to evaluate other vaccines that have reached safety and efficacy standards,” said Simao. “We encourage even more developers to come forward for review and assessment. It’s vitally important that we secure the critical supply needed to serve all countries around the world and stem the pandemic.”
On Dec. 2, the UK became the first Western country to approve a vaccine against Covid-19 when it gave the green light to one produced by US pharmaceutical giant Pfizer and German biotechnology company BioNTech. Russia had already been administering its Sputnik V vaccine.
Up to 50 countries including the US as well as the European Union have now approved vaccines for either emergency or normal use.
On Dec. 19, the US approved the Moderna vaccine as the second drug for use against Covid-19.On Wednesday, Britain’s drug regulator approved the Oxford-AstraZeneca Covid-19 vaccine for use in the UK, making it the first nation to do so. SOVEREIGNPH